Ahmad Al-Hamda, MD
Neurology with Special Qualifications in Child Neurology · Muscle Shoals, ALNPI 1851357586
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 464 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 51 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,715 and has fallen 65.9% since, to $584 in 2025.
Across 464 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$911
- AstraZeneca$800
- UCB, Inc.$439
- Lundbeck LLC$377
- Eisai Inc.$362
- plus $4K from 45 others
What the payments were for
- Speaking & faculty fees$230%
- Food & beverage$8,24899%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEGSEDI$138
- VNS - Sentiva$120
- BRILINTA$110
How this compares
$8,298 in reported general payments places this provider in the 70th percentile of 24 neurology with special qualifications in child neurology providers in Alabama.
See all neurology with special qualifications in child neurology providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 12 | $108,511 |
| BriviactBrivaracetam | 16 | $22,074 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,748 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 12 | $3,797 |
| Lacosamide | 23 | $3,303 |
| Primidone | 144 | $2,632 |
| Pyridostigmine Bromide | 15 | $1,563 |
| Levetiracetam | 45 | $1,242 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 70 | $1,168 |
| Topiramate | 123 | $1,057 |
| Amitriptyline Hcl | 90 | $1,053 |
| Carbamazepine | 19 | $821 |
| Midodrine Hcl | 12 | $746 |
| Lamotrigine | 68 | $701 |
| Divalproex Sodium | 16 | $667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact | $439 | $22,07416 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $144 | $1,56315 claims |
| Upsher-smith Laboratories LLCTopiramate | $51 | $1,057123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 24 neurology with special qualifications in child neurology providers in Alabama.
Other neurology with special qualifications in child neurology in Muscle Shoals
- Alyssa ReddyBirmingham$68K
- Alan PercyBirmingham$51K
- Kimberly LimboHuntsville$43K
- Michael LopezBirmingham$22K
- Elizabeth BebinBirmingham$15K
- Amitha AnanthBirmingham$10K
- Paul MaertensMobile$10K
- Jan MathisenBirmingham$8K
- Monisha GoyalBirmingham$8K
- Joshua SmithHuntsville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.